AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Stockholm, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805.BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic's portfolio of alpha-synuclein antibodies for Parkinson's disease and other potential indications. In 2019, a Phase 1 study of the lead asset, ABBV-0805, was initiated, and results from the study, presented at the International Congress of